Position Description

We are looking for individuals who share the importance of science-based selling, supported by a strong foundation of business analytics. The OAM will also possess a deep knowledge of the oral drug space, as well as background in later line oncology and or hematology malignancy. A solid understanding of the oncology therapeutic area is essential, with a preference for experience in RCC or GU Oncology. Demonstrated sales success and compassion for patients is required.

Responsibilities

• The OAM will promote safe and effective use of FOTIVDA (tivozanib) within the labeled indication (RCC) and in accordance with company training and policies
• Responsible for individual/territory sales performance and goal attainment
• Understand the Oncology/RCC environment; have in-depth knowledge of disease-state, local drivers, treatment and referral patterns, etc.
• Develop strong relationships with key customers practicing in your geography
• Prepare and implement a comprehensive business plan for territory
• Exercise sound judgment and ensure integrity and compliance with company policies in all activities and communications
• Foster company's core values and behaviors

Qualifications

• BS in Business or Science; 5 - 10 years sales experience in pharmaceutical/biotechnology industry
• Demonstrated understanding of oncology therapeutic area, products and marketplace strongly preferred
• Proven track record that demonstrates top sales accomplishments
• Demonstrated ability to understand and communicate technical clinical material clearly and effectively
• Ability to develop critical relationships with physicians, nurses and ancillary staff within academic hospitals, clinics, and private practice facilities
• Possesses a strong work ethic, ability to develop priorities and manage time appropriately.
• Works with all members of a team effectively
• Integrates innovative ideas in order to accomplish corporate and individual objectives
• Ability to travel and valid driver’s license in good standing required

Posted On: Tuesday, January 7, 2025